Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is xeroderma pigmentosum a contraindication for adjuvant radiation therapy to the breast in the breast conservation setting?
Answer from: Radiation Oncologist at Community Practice
It’s not a contraindication to RT as DSB caused by ionizing RT is not the same as damage caused by exposure to UV rays.
Sign in or Register to read more
8736
Related Questions
What are your top takeaways in Breast Cancer from ASTRO 2024?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
How do you manage symptomatic fat necrosis following adjuvant breast radiotherapy?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
What is the maximum dose that you would give to residual unresectable gross disease in the axilla in the setting of recurrent breast cancer s/p ALND?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?